应《网络安全法》要求，自2017年10月1日起，未进行实名认证将不得使用互联网跟帖服务。为保障您的帐号能够正常使用，请尽快对帐号进行手机号验证，感谢您的理解与支持！

24小时热门版块排行榜    

小木虫论坛-学术科研互动平台 » 生物医药区 » 新药研发 » 临床研究 » 求Ibrutinib 一个Ⅲ期临床试验和试验数据、结果
172/2返回列表上一页12
查看: 2231  |  回复: 16
只看楼主 @他人 存档 新回复提醒 (忽略) 收藏    在APP中查看

kdl0721

金虫 (著名写手)
引用回帖:
10楼: Originally posted by xiaoerduomao at 2014-04-09 09:50:28
这个3期临床还没结束呢，按照你给的是ongoing，并不是completed
http://scimore.asia:1080/pharmallPluswebsite/database/tpharma/cortallis/ibrutinib001755.htm

谢谢，这个三期临床试验由于结果呈显著阳性已经被FDA审查机构统一结束了，数据还没有公布，可能要到2014年ASCO年会上。你这个是汤森路透的数据？
赞一下 回复此楼
11楼2014-04-09 11:13:19
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

xiaoerduomao

金虫 (小有名气)
引用回帖:
11楼: Originally posted by kdl0721 at 2014-04-09 11:13:19
谢谢，这个三期临床试验由于结果呈显著阳性已经被FDA审查机构统一结束了，数据还没有公布，可能要到2014年ASCO年会上。你这个是汤森路透的数据？...

是的
回复此楼
12楼2014-04-09 11:36:52
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

dengchun14
13楼2014-04-09 11:43:16
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

kdl0721

金虫 (著名写手)
看来都没有知道该临床试验具体数据的，只能等2014ASCO年会了。
赞一下 回复此楼
14楼2014-04-09 13:36:44
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

kdl0721

金虫 (著名写手)
引用回帖:
12楼: Originally posted by xiaoerduomao at 2014-04-09 11:36:52
是的...

能给我发一份最新完整版的汤森路透报告吗？谢谢，金币都给你。
赞一下 回复此楼
15楼2014-04-09 13:39:23
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

kdl0721

金虫 (著名写手)
版主，请关闭该求助帖子，我已得到结果，谢谢！
赞一下(1人) 回复此楼
16楼2014-06-06 10:38:12
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

tsenghw

铁虫 (初入文坛)

【答案】应助回帖

N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators.
Collaborators (67)

Abstract
BACKGROUND:
In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.

METHODS:
In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.

RESULTS:
At a median follow-up of 9.4 months, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 months), as compared with a median of 8.1 months in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P<0.001). Ibrutinib also significantly improved overall survival (hazard ratio for death, 0.43; P=0.005). At 12 months, the overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group. The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% vs. 4.1%, P<0.001). An additional 20% of ibrutinib-treated patients had a partial response with lymphocytosis. Similar effects were observed regardless of whether patients had a chromosome 17p13.1 deletion or resistance to purine analogues. The most frequent nonhematologic adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related reactions, and cough in the ofatumumab group.

CONCLUSIONS:
Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL. (Funded by Pharmacyclics and Janssen; RESONATE ClinicalTrials.gov number, NCT01578707.).
赞一下 回复此楼
17楼2015-11-11 22:17:53
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 kdl0721 的主题更新
172/2返回列表上一页12
普通表情 龙 兔 虎 猫
最具人气热帖推荐 [查看全部] 作者 回/看 最后发表
[基金申请] 售SCI一区文章，我:8.O.55.1.O.54,科目齐全,可伽急 +4 jzg3xk1po8 2026-07-31 12/600 2026-08-01 17:50 by Kddn1pB6pAzX
[教师之家] 售SCI一区T0P文章，我:8.O55.1.O.54,科目全,可十急 +4 jzg3xk1po8 2026-07-31 9/450 2026-08-01 17:43 by Kddn1pB6pAzX
[考研] 售SCI一区T0P文章，我:8.O.55.1.O.5.4,科目全,可+急 +4 jzg3xk1po8 2026-07-31 12/600 2026-08-01 17:43 by Kddn1pB6pAzX
[论文投稿] 售SCI一区T0P文章，我:8.O.55.1.O.54,科目齐全,可+急 +3 jzg3xk1po8 2026-07-31 7/350 2026-08-01 17:42 by Kddn1pB6pAzX
[硕博家园] 售SCI一区文章，我:8.O.551.O.5.4,科目全,可伽急 +3 jzg3xk1po8 2026-07-31 9/450 2026-08-01 17:40 by Kddn1pB6pAzX
[基金申请] 面上再次挂了，太难了，躺也躺不了，倦也卷不过，小学校之殇！ +16 低垂的野花 2026-07-31 22/1100 2026-08-01 16:39 by Cathyau
[博后之家] 售SCI一区T0P文章，我:8.O55.1.O.54,科目全,可十急 +3 jzg3xk1po8 2026-07-31 9/450 2026-08-01 15:50 by y4XuShGyllvT
[公派出国] 售SCI-T0P文章，我:8O.5.5.1.O.54,科目齐全,可+急 +3 jzg3xk1po8 2026-07-31 6/300 2026-08-01 15:46 by y4XuShGyllvT
[基金申请] 2026年国自然面上资助率 +15 布布和一二 2026-07-30 19/950 2026-08-01 15:18 by 40862026
[基金申请] 微信指数没变化，科研之友没阅读 +14 wangze12014 2026-07-28 18/900 2026-07-31 18:35 by lzchaihuo
[教师之家] 基础研究怎么拉横向，学校到款任务越来越多，难以完成 拉横向，都有哪些途径啊 +8 锦衣卫寒战 2026-07-28 8/400 2026-07-31 18:13 by beefly
[高分子] HXDI做水性聚氨酯乳液，是不是特别容易出渣 15+3 yuyusuv 2026-07-29 3/150 2026-07-31 09:21 by huizingga
[基金申请] 系统今天又提示维护了，估计离放榜不远了 +11 winnerche 2026-07-29 15/750 2026-07-30 23:08 by jnhyjjm
[考博] 申请2027年材料/化学类博士 10+3 考研老狗? 2026-07-25 5/250 2026-07-30 19:33 by 白色木鱼
[基金申请] 你们的时间戳变了吗 +3 archvillain 2026-07-30 4/200 2026-07-30 18:53 by levinzhwen
[基金申请] 今年的WR进展到哪一步了？ +5 wsgjhwz 2026-07-25 9/450 2026-07-30 12:59 by 可淡不可忘
[基金申请] 时间戳他又来了 +14 晓晓爱翠翠 2026-07-26 17/850 2026-07-29 16:30 by 呵呵二哥
[基金申请] 这种情况还有戏吗 +5 drbart 2026-07-27 11/550 2026-07-29 05:50 by drbart
[基金申请] 同事接到电话了，我却没有 +4 1234567wang 2026-07-27 4/200 2026-07-28 10:11 by GOODLUCKER
[基金申请] 准备明年的基金了 +5 Tide man 2026-07-27 5/250 2026-07-28 09:25 by newfuzzy1
信息提示
关闭
请填处理意见
关闭